Cart
sales@molnova.com
ML-193
CAS No. 713121-80-3
ML-193( CID 1261822 )
Catalog No. M24723 CAS No. 713121-80-3
ML-193 is a potent and selective GPR55 antagonist( IC50 : 221 nM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 43 | In Stock |
|
| 5MG | 72 | In Stock |
|
| 10MG | 125 | In Stock |
|
| 25MG | 258 | In Stock |
|
| 50MG | 410 | In Stock |
|
| 100MG | 605 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameML-193
-
NoteResearch use only, not for human use.
-
Brief DescriptionML-193 is a potent and selective GPR55 antagonist( IC50 : 221 nM).
-
DescriptionML-193 is a potent and selective GPR55 antagonist( IC50 : 221 nM). It shows more than 27-fold selectivity for GPR55 over GPR35, CB1 and CB2, and can improve the motor and the sensorimotor deficits of Parkinson’s disease (PD) rats.
-
In VitroML-193 (0.01-100 μM; pretreated for 15 min) inhibits β-arrestin trafficking induced by L-α-lysophophosphatidylinositol (LPI, 10 μM) and ML186 (1 μM) with IC50s of 0.22 μM and 0.12 μM, respectively.ML-193 (0.01-10 μM; pretreated for 30 min) decreases the LPI-mediated ERK1/2 phosphorylation, with an IC50 of 0.2 μM in U2OS cells.ML-193 (5 μM; pretreated for 30 min) attenuates the GPR55 agonists induced increases in hNSCs proliferation rates.ML-193 (5 μM; 10 d) attenuates the ML184-induced increases in hNSCs differentiation.
-
In VivoML193 (1 and 5 μg/rat; intra-striatal at a rate of 1 μL/min) attenuates sensorimotor deficits and slip steps, increases motor coordination in PD rats. Animal Model:Male Wistar rats (200-250 g) were induced experimental Parkinson by 6-hydroxydopamine (6-OHDA, 10 μg/rat)Dosage:1 and 5 μg/rat Administration:Injected into the right striatum at a rate of 1 μL/min Result:Increased the time on the rotarod, decreased latency to remove the label and slip steps in 6-OHDA-lesioned rats.
-
SynonymsCID 1261822
-
PathwayGPCR/G Protein
-
TargetCannabinoid Receptor
-
RecptorGPR55
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number713121-80-3
-
Formula Weight527.59
-
Molecular FormulaC28H25N5O4S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 33.33 mg/mL (63.17 mM)
-
SMILESCc1c(NS(c(cc2)ccc2NC(c2cc(-c3ncccc3)nc3c(C)cc(C)cc23)=O)(=O)=O)onc1C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Fatemi I, et, al. The effect of intra-striatal administration of GPR55 agonist (LPI) and antagonist (ML193) on sensorimotor and motor functions in a Parkinson's disease rat model. Acta Neuropsychiatr. 2021 Feb;33(1):15-21.
molnova catalog
related products
-
AM6545
AM6545 is a selective and potent peripheral restricted cannabinoid receptor 1 (CB1) antagonist that inhibits the CB2 receptor, ameliorates hypometabolic obesity and improves adipokine secretion in monosodium glutamate-induced obese mice, and may be useful in the study of obesity and diabetes.
-
Drinabant
Drinabant is an orally active CB1 receptor antagonist. Drinabant inhibits the agonist-stimulated calcium signal with IC50 values of 25 nM and 10 nM for the hCB1-R and rCB1-R, respectively, and is ineffective for the hCB2-R.
-
AM251
AM251 is a potent CB1 receptor antagonist (IC50 = 8 nM, Ki = 7.49 nM) that displays 306-fold selectivity over CB2 receptors; also potent GPR55 agonist (EC50 = 39 nM).
